【Everlight Bio-Tech】Announcement of the company's board of directors' approval of the Q1 2026 individual financial report

1. Date of board resolution: 2026/04/29 2. Date of audit committee approval: 2026/04/24 3. Reporting period for financial report or annual self-compiled financial information (YYYY/MM/DD~YYYY/MM/DD): 2026/01/01~2026/03/31 4. Operating revenue accumulated from January 1 to the end of this period (in thousands of NTD): 368,422 5. Operating gross profit (loss) accumulated from January 1 to the end of this period (in thousands of NTD): 137,464 6. Operating income (loss) accumulated from January 1 to the end of this period (in thousands of NTD): 54,731 7. Pre-tax net profit (loss) accumulated from January 1 to the end of this period (in thousands of NTD): 53,254 8. Net profit (loss) for this period accumulated from January 1 to the end of this period (in thousands of NTD): 43,737 9. Net profit (loss) attributable to owners of the parent company accumulated from January 1 to the end of this period (in thousands of NTD): 43,737 10. Basic earnings (loss) per share accumulated from January 1 to the end of this period (in NTD): 0.60 11. Total assets at period end (in thousands of NTD): 1,715,737 12. Total liabilities at period end (in thousands of NTD): 319,761 13. Equity attributable to owners of the parent company at period end (in thousands of NTD): 1,395,976 14. Other matters to be specified: None